Average Co-Inventor Count = 8.12
ph-index = 5
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Merck Sharp + Dohme Corp. (32 from 2,405 patents)
2. Albany Molecular Research, Inc. (3 from 97 patents)
3. Merck + Co., Inc. (1 from 4,770 patents)
4. Jiangsu Hengrui Medicine Company Ltd. (1 from 159 patents)
5. Shanghai Hengrui Pharmaceutical Co., Ltd. (1 from 100 patents)
6. Merck Sharp + Dohme B.v. (1 from 55 patents)
7. Merck Sharp & Dohme LLC (1 from 13 patents)
8. Sanofi Pasteur Biologics, LLC (24 patents)
35 patents:
1. 12516046 - 2-oxo-oxazolidine-5-carboxamides as NAV1.8 inhibitors
2. 12365674 - Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection
3. 12344595 - 2-amino-n-phenyl-nicotinamides as NAV1.8 inhibitors
4. 12331044 - Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection
5. 12281109 - Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
6. 12246008 - 4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels
7. 12209145 - PCSK9 antagonist compounds
8. 12195445 - 2-amino-N-heteroaryl-nicotinamides as Na1.8 inhibitors
9. 12178842 - PCSK9 antagonist compounds
10. 11976069 - Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection
11. 11802122 - 2-oxoimidazolidine-4-carboxamides as NA1.8 inhibitors
12. 11484565 - PCSK9 antagonist compounds
13. 11427616 - PCSK9 antagonist compounds
14. 11377438 - 2-amino-n-heteroaryl-nicotinamides as Na1.8 inhibitors
15. 11332492 - CD73 inhibitors and therapeutic uses thereof